Navigation Links
VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
Date:8/31/2012

SEATTLE, Aug. 31, 2012 /PRNewswire/ -- VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.

(Logo: http://photos.prnewswire.com/prnh/20120831/SF65959LOGO)

CP-870,893 is a potent CD40 agonist that has been evaluated in a number of preclinical and clinical trials to date. These studies have determined the safety profile, pharmacokinetics and pharmacodynamic parameters of CD40-mediated immune activation as well as the maximum tolerated dose of the antibody.  VLST plans to advance this compound into efficacy studies in an oncology setting.  VLST is currently evaluating multiple clinical opportunities.  Under the terms of the agreement, Pfizer will retain co-exclusive rights to CP-870,893 in the oncology vaccine field.

"We are excited to in-license this promising compound. With the transfer of the IND from Pfizer, we will accelerate the development of our clinical strategy and expand our focus in immunotherapy to include oncology," said Martin Simonetti, President and Chief Executive Officer of VLST.  "Our recent financing will help support our Phase 2 clinical efforts."

"This agreement with VLST is yet another example of how Pfizer is executing against its portfolio management goals in oncology while finding a positive way forward for those compounds leaving our pipeline," said Garry Nicholson, President and General Manager of Pfizer Oncology.  "VLST's expertise in immunotherapy makes the company a strong partner to continue the development of this compound and potentially deliver a new therapy to patients with cancer."

VLST completed a tranche of the Series B financing of $5 million in June 2012. The financing was led by ARCH Venture Partners and included OVP Venture Partners, WRF Capital and Versant Ventures.

About VLST
VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel therapeutics for the treatment of cancer and inflammatory and autoimmune disorders. The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies.  The VLST discovery platform has primary applications for the treatment of cancer and inflammatory and autoimmune diseases.  For more information, please visit www.vlstcorp.com.

Contact:
Julie Rathbun
Rathbun Communications, Inc.
julie@rathbuncomm.com
(206) 769-9219


'/>"/>
SOURCE VLST Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MGC Diagnostics Corporation Completes Sale of New Leaf Business Assets to Life Time - The Healthy Way of Life Company
2. MGC Diagnostics Corporation Reports Third Quarter Fiscal Year 2012 Operating Results
3. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
4. The Hygenic Corporations Custom Rubber Solutions Solve Industry Problems
5. MGC Diagnostics Corporation to Report Third Quarter Fiscal 2012 Financial Results on Thursday, August 30, 2012
6. Kewaunee Scientific Corporation Declares Quarterly Dividend
7. Siemens Healthcare Enters into Definitive Agreement to Acquire Penrith Corporation
8. MGC Diagnostics Corporation Launches New Corporate Website and Unveils New Logo
9. Comprehensive Care Corporation Names Jairo Estrada Senior Management Advisor To Assist in Growing the Companys New Pharmacy Initiatives
10. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Masimo Corporation in Connection with Executive Compensation
11. SpineMark Corporation Partners with PhDx and Millennium Environmental to Create an ISO type Spine Protocol Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):